Medicare Enrolled

Dr. Ibrahim Shalaby, MD

Medical Oncology · Lubbock, TX
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
4101 22ND PL, Lubbock, TX 79410
8067258000
Registered in NPPES since 2006
NPI: 1053374769 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Shalaby from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Shalaby? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Shalaby

Dr. Ibrahim Shalaby is a medical oncology specialist in Lubbock, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Shalaby performed 1,528 Medicare services in 2023. These records do not provide a deduplicated patient total.

Between the years covered by Open Payments, Dr. Shalaby received a total of $9,272 from 46 pharmaceutical and/or device companies across 177 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Shalaby is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years of NPI registration ▲ Top 50% volume in TX $9,272 industry payments

Medicare Practice Summary — 2023

Medicare Utilization ↗
1,528
Medicare services
Top 50% in TX for medical oncology
Not available
Unique patients (not deduplicated)
$65
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
763 $66 $172
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
326 $40 $111
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
164 $60 $115
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
69 $100 $250
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
62 $91 $164
New patient office visit, complex (60-74 min) 61 $127 $361
Hospital follow-up visit, low complexity
Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service.
30 $38 $70
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
23 $90 $285
Initial hospital admission, moderate complexity
Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter.
17 $100 $405
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
13 $133 $600
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.

Industry Payment Transparency

Open Payments through 2024 ↗
$9,272
Total received (2018-2024)
Avg $1,325/year across 7 years
Top 39% in TX for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
46
Companies
177
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →

Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$332
2023
$6,204
2022
$384
2021
$402
2020
$336
2019
$760
2018
$854

Payments by company (2024)

AstraZeneca Pharmaceuticals LP
$64
PFIZER INC.
$51
ABBVIE INC.
$47
Amgen Inc.
$33
Adaptive Biotechnologies Corporation
$28
SERVIER PHARMACEUTICALS LLC
$25
Genentech USA, Inc.
$23
Genmab U.S., Inc.
$22
Celgene Corporation
$22
E.R. Squibb & Sons, L.L.C.
$18
Top 3 companies account for 48.7% of 2024 payments
All-time payments by company (2018-2024) ›
Gilead Sciences, Inc.
$6,145
PFIZER INC.
$313
AstraZeneca Pharmaceuticals LP
$291
Novartis Pharmaceuticals Corporation
$260
Pharmacyclics LLC, An AbbVie Company
$193
Merck Sharp & Dohme Corporation
$182
E.R. Squibb & Sons, L.L.C.
$159
Amgen Inc.
$157
Seattle Genetics, Inc.
$126
Epizyme, Inc.,
$100
SANOFI-AVENTIS U.S. LLC
$100
Janssen Products, LP
$100
PUMA BIOTECHNOLOGY, INC.
$100
Genentech USA, Inc.
$99
Puma Biotechnology, Inc.
$93
Janssen Biotech, Inc.
$85
Takeda Pharmaceuticals U.S.A., Inc.
$84
ABBVIE INC.
$47
Celgene Corporation
$40
Incyte Corporation
$39
Daiichi Sankyo Inc.
$38
EMD Serono, Inc.
$35
Seagen Inc.
$35
Jazz Pharmaceuticals Inc.
$33
Astellas Pharma US Inc
$30
Eisai Inc.
$30
Adaptive Biotechnologies Corporation
$28
Boehringer Ingelheim Pharmaceuticals, Inc.
$28
Nestle HealthCare Nutrition Inc.
$25
SERVIER PHARMACEUTICALS LLC
$25
Rigel Pharmaceuticals, Inc.
$24
Genmab U.S., Inc.
$22
Blueprint Medicines Corporation
$21
AbbVie, Inc.
$20
Organogenesis Inc.
$19
Dova Pharmaceuticals
$17
GENZYME CORPORATION
$17
Lilly USA, LLC
$16
JAZZ PHARMACEUTICALS INC.
$14
TESARO, Inc.
$14
Amarin Pharma Inc.
$13
Verastem, Inc.
$13
Taiho Oncology, Inc.
$12
MEDIVATION FIELD SOLUTIONS LLC
$11
Teva Pharmaceuticals USA, Inc.
$11
Clovis Oncology, Inc.
$10
Top 3 companies account for 72.8% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · AYVAKIT · Apligraf · Avastin · BENDEKA · BOSULIF · Bavencio · CALQUENCE · Copiktra · DARZALEX · DAURISMO · Doptelet · ELREXFIO · EMEND · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · Enhertu · Epkinly · FASLODEX · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMDELLTRA (AMG 757) · IMFINZI · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MVASI · NERLYNX · NINLARO · Nerlynx · Neulasta · OPDIVO · ORGOVYX · PADCEV · PLUVICTO · PROMACTA · RYDAPT · Revlimid · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SPRYCEL · SUTENT · TAGRISSO · TASIGNA · TAXOTERE · TAZVERIK · TECENTRIQ · Tavalisse · Tibsovo · Trodelvy · VENCLEXTA · VYXEOS · Vascepa · Venclexta · XALKORI · XTANDI · ZEJULA · ZENPEP · ZYTIGA · clonoSEQ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Looking for a medical oncology specialist in Lubbock?
Compare medical oncologists in the Lubbock area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists in nearby ZIP areas
4
County median income
$63,367
Nearest hospital to ZIP centroid (approximate)
COVENANT MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES NPPES snapshot; verify current record
Medicare Enrollment PECOS PECOS snapshot
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not included N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Shalaby is a clinical cardiology specialist, with moderate Medicare volume, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Shalaby experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Shalaby performed 763 office visit, established patient (30-39 min) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Shalaby receive payments from pharmaceutical companies?
Yes. Dr. Shalaby received a total of $9,272 from 46 companies across 177 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Shalaby's costs compare to other medical oncologists in Lubbock?
Dr. Shalaby's average Medicare payment per service is $65. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Shalaby) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
About this page

This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Industry payment disclosure alone establishes neither wrongdoing nor legality. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →